Aleglitazar

• CAT Number: I003657
• CAS Number: 475479-34-6
• Molecular Formula: C24H23NO5S
• Molecular Weight: 437.51
• Purity: ≥95%
• Synonyms: (2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]propanoic acid
• Target: Vitamin D Related/Nuclear Receptor
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ)
• InChI: InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1
• InChIKey: DAYKLWSKQJBGCS-NRFANRHFSA-N
• SMILES: CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)C[C@@H](C(=O)O)OC

Aleglitazar（Cat No.:I003657）is a dual PPAR (peroxisome proliferator-activated receptor) agonist that targets both PPARα and PPARγ, receptors involved in regulating lipid and glucose metabolism. By activating these receptors, Aleglitazar aims to improve insulin sensitivity, reduce inflammation, and modulate lipid levels. It has been investigated primarily for the treatment of type 2 diabetes and dyslipidemia, with potential benefits in managing metabolic syndrome and cardiovascular risk factors. Clinical trials have explored Aleglitazar’s efficacy in improving glycemic control and lipid profiles, though its safety and long-term effectiveness are still under investigation.